首页> 外文期刊>The annals of pharmacotherapy >Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
【24h】

Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

机译:将指南转化为实践:解释2016年ACC专家共识决策途径,以非他汀类药物治疗在动脉粥样硬化疾病风险管理中降低的LDL-Cholesterol的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: In 2016, the American College of Cardiology released a decision pathway, based on expert consensus, to guide use of non-statin agents in the management of atherosclerotic cardiovascular disease risk. The purpose of this article is to assist practitioners, health systems and managed care entities with interpreting this consensus statement in order to simplify implementation of the recommendations into patient care. Methods: Major themes from the consensus statement are briefly summarized and explained. Drug therapy recommendations are condensed into a single algorithm, while tables correlate each recommended regimen with the appropriate patient population from both a patient-level and systems-level perspective. Finally, a patient case with evidence-based decision support is explored. Results: These tools allow practitioners to make appropriate patient-specific decisions about the use of non-statin pharmacotherapy and enable health systems and managed care entities to more readily identify guideline-appropriate use of these agents upon review of patient profiles or prescribing patterns. Conclusion: This article provides resources for healthcare providers that facilitate uptake of these recommendations into clinical practice.
机译:目的:2016年,美国心脏病学基于专家共识发布了决策途径,以指导在动脉粥样硬化心血管疾病风险管理中使用非他汀类药物的使用。本文的目的是协助从业者,卫生系统和托管护理实体解释这一共识声明,以简化患者护理的建议。方法:简要概述并解释了共识声明的主要主题。药物治疗建议被凝结成单一算法,而表表将每个推荐的方案与患者水平和系统级视角的适当患者人口相关联。最后,探讨了患有基于证据的决策支持的患者案例。结果:这些工具允许从业者对使用非他汀类药物治疗以及使卫生系统和管理护理实体进行适当的患者特异性决策,以便在审查患者简档或处方模式时适当地确定这些药剂的准则。结论:本文为医疗保健提供者提供资源,促进将这些建议的加强到临床实践中。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号